Edition:
Deutschland

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

98.50USD
19:22 Uhr
Change (% chg)

$1.05 (+1.08%)
Prev Close
$97.45
Open
$97.84
Day's High
$98.64
Day's Low
$97.09
Volume
344,827
Avg. Vol
1,818,177
52-wk High
$125.84
52-wk Low
$69.47

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Buy/Sell

Sell Hold Buy
2.41 Mean rating from 22 analysts

Overall

Beta: 1.53
Market Cap(Mil.): $144,249.59
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.64
Yield (%): 2.83

US STOCKS-Tech stocks weigh on Wall Street

* Indexes down: Dow 0.4 pct, S&P 0.8 pct, Nasdaq 1.6 pct (Updates to late afternoon; changes byline; adds NEW YORK to dateline)

AbbVie cash cow Humira barely beats sales estimates, stock slides

AbbVie Inc's blockbuster arthritis drug Humira barely beat Wall Street sales forecasts, raising concerns about its future viability as a cash cow and sending the drugmaker's shares down 5 percent on Friday.

US STOCKS-Tech, healthcare stocks weigh on Wall Street

* Indexes down: Dow 0.58 pct, S&P 0.97 pct, Nasdaq 1.86 pct (Adds comment, updates prices)

UPDATE 2-AbbVie cash cow Humira barely beats sales estimates, stock slides

* Stock down 5 percent in afternoon trade (Adds details from conference call, updates share movement)

US STOCKS-Wall Street dips as Intel drags tech stocks lower

* Dow up 0.12 pct, S&P dips 0.16 pct, Nasdaq down 0.56 pct (Changes comment, adds details, updates prices)

AbbVie tops second-quarter estimates, sets higher earnings target

July 27 AbbVie Inc on Friday topped Wall Street estimates for second-quarter profit and raised its yearly earnings forecast, led by stronger demand for top-selling drugs Humira and Imbruvica.

Photo

Citron's Left reiterates belief AbbVie shares will fall sharply

NEW YORK Short-seller Andrew Left's Citron Research expanded on his prediction that U.S. drugmaker AbbVie Inc's stock would fall to $60 a share, arguing that new regulations to speed biosimilar drugs to the market and reform rebates will hurt revenue from the company's top-selling drug, Humira.

UPDATE 1-Citron's Left reiterates belief AbbVie shares will fall sharply

NEW YORK, July 24 Short-seller Andrew Left's Citron Research expanded on his prediction that U.S. drugmaker AbbVie Inc's stock would fall to $60 a share, arguing that new regulations to speed biosimilar drugs to the market and reform rebates will hurt revenue from the company's top-selling drug, Humira.

Citron's Left reiterates belief AbbVie shares will fall sharply

NEW YORK, July 24 Short-seller Andrew Left's Citron Research expanded on his prediction that U.S. drugmaker AbbVie Inc's stock would fall to $60 a share, arguing that new regulations to speed biosimilar drugs to the market and reform rebates will hurt revenue from the company's top-selling drug, Humira.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.51%
Rohstoffe +0.52%
Industrie +0.57%
Konjunktur abhängige Waren & Dienstleistungen +1.03%
Konjunktur unabhängige Waren & Dienstleistungen +0.88%
Finanzindustrie +0.64%
Pharma +0.65%
Technologie +0.74%
Telekommunikation +0.66%